National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Raxone® is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).

NCPE Assessment Process Complete
Rapid review received 10/02/2016
Rapid review completed 14/04/2016
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by the HSE 28/06/2017
Pre-submission consultation with Applicant 25/07/2017
Submission received from Applicant 17/11/2017
Preliminary review sent to Applicant 10/05/2018
NCPE assessment re-commenced 22/06/2018
Factual accuracy sent to Applicant 30/07/2018
NCPE assessment re-commenced 15/08/2018
NCPE assessment completed 28/08/2018
NCPE assessment outcome The NCPE recommends that idebenone not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary